BridgeMD
A Continuation Study of Latozinemab in Participants with Neurodegenerative Disease
EU CTIS ID: 2023-506805-20-01
What this study is testing
To provide continued access to latozinemab for participants who have previously participated in a latozinemab study sponsored by Alector, or in partnership or collaboration with Alector.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Has provided informed consent for this study. Participants unable to provide consent on their own behalf are not eligible.
- Has successfully completed participation in their previous latozinemab study (e.g., AL001-2 or AL001-3).
- At the first visit, women must be nonpregnant and nonlactating, and one of the following conditions must apply: a. Not a woman of childbearing potential b. Is a woman of childbearing potential and agrees to use a highly effective contraceptive method from the first visit until 10 weeks after the last dose of study treatment. c. Women of childbearing potential must have a serum or urine pregnancy test conducted at the Transition Visit.
- Men must agree to use acceptable contraception and not donate sperm from the first visit until 10 weeks after the last dose of study treatment.
- Agrees not to donate blood or blood products for transfusion for the duration of the study and for 1 year after the final dose of study treatment.
- Willing to and can comply with the study protocol requirements, in the opinion of the investigator.
You likely can't join if
- Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.
- Significant kidney disease.
- Impaired liver function.
- Clinically significant blood abnormalities.
- Presence of an abnormal ECG that is clinically significant.
- Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the participant’s well-being or safety.
The study team makes the final eligibility decision.
Where it's taking place
- Canada
- United States
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Canada; United States; United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.